When GLP-1 drugs may be appropriate for lipoedema With all of the above said, there are circumstances where GLP-1 drugs may be a reasonable consideration for women with lipoedema: When prediabetes or type 2 diabetes is present and not adequately controlled through nutrition alone When chronic stress and cortisol dysregulation are significantly impairing metabolic function and the ability to lose abdominal weight, despite a well-structured nutrition protocol When these decisions are made collaboratively with a medical team that understands lipoedema and is actively monitoring muscle mass, bone health, nutritional status, and mental health In all cases, a low-inflammatory, nutritionally balanced eating approach remains essential alongside the medication: GLP-1 drugs are not a replacement for good nutrition
In fact, MitoQ has been used in a range of in vivo studies, in rats and mice, and in two phase II human trials demonstrating that it can be safely delivered to patients with promising results, lending further support that mitochondria-targeted antioxidants may be applicable to a wide range of human pathologies that involve mitochondrial oxidative damage (Smith and Murphy, 2010)
Harmful disturbances and poor healing of rectovaginal fistulas in patients (Klicek et al., 2008
IKK primes inflammasome formation by recruiting NLRP3 to the trans-Golgi network
What users commonly report: Continued gradual fat loss, but slower than weeks 6-8 Body composition improvements consolidate Some users plateau around week 10 Decision point: Most protocols recommend stopping at 8-12 weeks with a 4-6 week break before repeating
NAD+ injections are being explored by a wide range of adults
